Carboxy derivatives with antiinflamatory properties

A compound of formula (I):

• wherein,
• represents a 5 membered heteroaryl ring, which in addition to the C═N shown contains one or more further heteroatoms independently selected from the group consisting of N, O and S;
• or
• represents a 6 membered heteroaryl ring, which in addition to the C═N shown optionally contains one or more further N atoms;
• RA1 is (CH2)0-2-phenyl;
• wherein RA1 is optionally substituted by one or more substituents selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, hydroxy, cyano, OG1, S(O)0-2G1, SF5, (CH2)0-3C3-7 cycloalkyl and 5-7-membered heterocyclyl wherein said C3-7 cycloalkyl and said 5-7-membered heterocyclyl are optionally substituted by one or more groups selected from the group consisting of halo, C1-3 alkyl and C1-3 haloalkyl;
• wherein two alkyl groups which are attached to the same carbon atom are optionally joined to form a C3-7 cycloalkyl ring;
• wherein the C3-10 cycloalkyl group is optionally fused to a phenyl ring which phenyl ring is optionally substituted by one or more halo atoms;
• or RA1 is optionally substituted by one phenyl ring which is optionally substituted by C1-2 haloalkyl, C1-2 haloalkoxy or one or more halo atoms;
• wherein G1 is C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, or (CH2)0-1phenyl wherein G1 is optionally substituted by one or more substituents selected from the group consisting of halo, C1-2 alkyl, C1-2 haloalkyl, hydroxy, cyano, nitro, C1-2 alkoxy and C1-2 haloalkoxy;
• RA2 is selected from the group consisting of halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, hydroxy, cyano, nitro, NR1R2, OG2 and S(O)0-2G2;
• wherein G2 is C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, or phenyl which is optionally substituted by one or more substituents selected from the group consisting of halo, C1-2 alkyl, C1-2 haloalkyl, hydroxy, cyano, nitro, C1-2 alkoxy and C1-2 haloalkoxy;
• and
• wherein R1 and R2 are independently H or C1-2 alkyl or, taken together, R1 and R2 may combine to form a 5-7-membered heterocyclic ring;
• or RA2 is absent;
• and
• RC and RD are each independently H, C1-2 alkyl, hydroxy, fluoro or C1-2 alkoxy;
• or RC and RD may join to form a C3-5 cycloalkyl ring;
• and wherein
• the total number of carbon atoms in groups RA1 and RA2 taken together including their optional substituents is 6-14;
• or a pharmaceutically acceptable salt and/or solvate thereof.